Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences' Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of Cancer
Updated data from ARC-7, the randomized Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, will be presented in a special ASCO plenary series rapid abstract update session... | May 17, 2023
United States Terry Rosen American Society Of Clinical Oncology Gilead Sciences Arcus Biosciences Inc Arcus Biosciences
Source: marketscreener.com